Heart Test Laboratories Inc Ordinary Shares HSCS 深 沪
已收盘 12-19 16:00:00 美东时间
2.35
+0.160
+7.31%
华盛通- 最 高3.00
- 今 开2.22
- 成交量 8.44万股
- 最 低 2.16
- 昨 收 2.19
- 总市值 1906.37万
- 52周最高 6.47
- 市盈率 静 --
- 换手率 1.04%
- 52周最低 2.01
- 委 比 -97.04%
- 总股本 811.22万
- 历史最高 8.7044
- 量 比 2.12
- 振 幅 38.36%
- 历史最低 0.05
- 每 手 1
- 风险率 0.43%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多基金市场周报（20250630-20250704）：智选科创价值50指数分析
（转自：财信证券研究） 新发行基金情况 本周（20250630-20250704），拟发行基金33只。分类型看，被动指数型股票基金21只、混合债券型基金（二级...
07-02 08:05
HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis
HeartSciences' AI-ECG algorithm for detecting aortic stenosis has received FDA Breakthrough Device designation. The algorithm uses advanced deep learning techniques to detect moderate-to-severe AS up to 24 months earlier than traditional methods and integrates seamlessly with hospital EHR systems.
06-04 13:00
Foundational US Patent Granted for ECG Assessment of Heart Function, Further Expands HeartSciences’ Patent Portfolio and IP Value
HeartSciences Inc.获得一项新专利，使用ECG估算心脏功能，提升心脏病诊断能力。公司已获44项专利，显示其在AI-ECG领域的领先地位。首席执行官表示，该专利强化了公司的市场地位，并提升了其知识产权的价值。
06-03 13:00
HeartSciences Signs First MyoVista Insights™ Platform Customer, Marking Major Commercial Milestone
HeartSciences Inc. announced its first commercial customer for the MyoVista Insights™ platform, Westcliffe Health Innovations in the UK. The cloud-based AI-powered ECG management system aims to improve clinical decision-making and healthcare efficiency.
05-29 13:00
HeartSciences Closes Non-Dilutive Financing With $19M In Net Proceeds, Increasing Its Cash Runaway Ahead Of Upcoming FDA Submission
Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS, HSCSW))) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save
2024-09-12 21:01
